SearchSearch results for: “”

In deze blog signaleren wij kort enkele belangwekkende bestuursrechtelijke en omgevingsrechtelijke uitspraken van de afgelopen periode.

Since the implementation of the Dutch scheme of arrangement on 1 January 2021, a relatively new tool to restructure debts of Dutch corporate entities in order to prevent their insolvency is available in the Netherlands.

In dit artikel schetsen Anna Collignon, Liesbeth Berkouwer en Jelmer Ypinga de ontwikkelingen die zich in de afgelopen periode - sinds hun vorige bijdrage - hebben voorgedaan.

In deze blog signaleren wij kort enkele belangwekkende bestuursrechtelijke en omgevingsrechtelijke uitspraken van de afgelopen periode.

Michael Molenaars, Jeroen Smits, Reinout de Boer and Rogier van der Struijk contributed to Chambers: Corporate Tax 2024 in a chapter about Law and Practice in the Netherlands.

On Thursday 16 May 2024, the four political parties (forming the new Dutch government) which have been negotiating for the past several months came to an agreement (Hoofdlijnenakkoord 2024) in which their plans and policies are laid down.

In deze blog signaleren wij kort enkele belangwekkende bestuursrechtelijke en omgevingsrechtelijke uitspraken van de afgelopen periode.

Stibbe lawyers Marieke Driessen, Loes van Dijk and Ingrid van der Klooster contributed to the book 'Sustainable Finance in Europe' which was recently published.

On 23 May 2024, the Luxembourg Minister of Finance presented a new draft law to Parliament, packed with notable tax provisions.

In October 2024, the European Council adopted the EU Listing Act, a legislative package that includes changes to the Market Abuse Regulation. We discuss the expanded exemptions to the prohibition of PDMRs carrying out transactions during a closed period.

Gelet op een arrest van de Hoge Raad uit 2020 en de beschikbare feitenrechtspraak leek de deur voor niet-ontvankelijkheid van het OM bij serieuze overschrijdingen van de redelijke termijn even op een kier te staan.

The European Court of Justice has upheld the annulment of Intel’s EUR 1.06 billion fine for abuse of dominance. The judgment provides guidance on how to assess the anti-competitiveness of loyalty rebates.

Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.